Pharmacopeia Targets 2009 For SARM Phase II After Gaining Program From Bristol
This article was originally published in The Pink Sheet Daily
Executive Summary
Company licenses the Phase I selective androgen receptor modulator for muscle wasting from Bristol in exchange for research support.
You may also be interested in...
Big Pharma Has Eye On Pharmacopeia’s DARA For Blood Pressure
DARA, a first-in-class dual-acting angiotensin and endothelin receptor antagonist in development for hypertension and diabetic nephropathy, is in Phase II development.
Big Pharma Has Eye On Pharmacopeia’s DARA For Blood Pressure
DARA, a first-in-class dual-acting angiotensin and endothelin receptor antagonist in development for hypertension and diabetic nephropathy, is in Phase II development.
Merck Gains Phase II SARM For Muscle Loss With GTx Deal
Merck, GTx pool their selective androgen receptor modulator programs in a deal valued at over $500 million.